CRUSE® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Neisinger, Sophia
- dc.contributor.author Giménez Arnau, Anna Maria
- dc.contributor.author Maurer, Marcus
- dc.date.accessioned 2025-04-11T05:52:47Z
- dc.date.available 2025-04-11T05:52:47Z
- dc.date.issued 2024
- dc.description.abstract Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE® , the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.
- dc.format.mimetype application/pdf
- dc.identifier.citation Neisinger S, Sousa Pinto B, Ramanauskaite A, Bousquet J, Weller K, Metz M, et al. CRUSE® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clin Transl Allergy. 2024 Jan;14(1):e12328. DOI: 10.1002/clt2.12328
- dc.identifier.doi http://dx.doi.org/10.1002/clt2.12328
- dc.identifier.issn 2045-7022
- dc.identifier.uri http://hdl.handle.net/10230/70129
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Clin Transl Allergy. 2024 Jan;14(1):e12328
- dc.rights © 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Chronic urticaria self evaluation (CRUSE®) app
- dc.subject.keyword Digital tools
- dc.subject.keyword mHealth apps
- dc.subject.keyword Patient-reported outcome measures
- dc.subject.keyword Wheals and angioedema
- dc.title CRUSE® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion